NAGOJA, Japonsko, 21. dubna 2025 /PRNewswire/ -- Společnost Kowa Company, Ltd. (sídlo: Nagoja, prefektura Aiči, Japonsko) dnes oznámila připravovanou prezentaci neklinických dat pro K-679, svůj nový konjugát protilátka-léčivo (antibody drug-loaded unimicelle conjugate, ADUC) s...
Hence then, the article about k 679 novy unimicelarni konjugat protilatka lecivo s mimoradne vysokou vazebnou kapacitou pro lecivo vykazuje vynikajici ucinnost u solidnich nadoru exprimujicich egfr was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( K-679: Nový unimicelární konjugát protilátka-léčivo s mimořádně vysokou vazebnou kapacitou pro léčivo vykazuje vynikající účinnost u solidních nádorů exprimujících EGFR )
Also on site :
- Primary school teacher banned after drinking can of beer in classroom and eating mints after every sip
- Greenland warns of ‘red lines’ in talks with US
- A New Lawsuit Is Taking Aim at Costco’s Beloved $4.99 Rotisserie Chicken